Philips integrates MedChat’s AI capabilities to optimize automated patient communication and hospital workflows

November 22, 2021

  • Collaboration adds Medchat’s live chat and chatbot services to Philips patient management and informatics platform, Patient Navigation Manager
  • Combined offering allows customers in North America to digitally navigate patients using advanced chatbot services to streamline workflows, quickly resolve patient requests and improve contact center efficiency

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced a collaboration with USA-based MedChat to integrate MedChat’s live chat and AI-driven chatbot services into Philips Patient Navigation Manager, helping improve call center efficiency and speed the time to resolve patient inquiries. With the combined offering, Philips now enables its customers in North America to create automated communication workflows that function seamlessly alongside patient access and call center operations. Hospitals and outpatient clinics can also digitally navigate patients from the time an order is placed, to when it is scheduled and completed through follow-up.

Patient Navigation Manager automatically guides patients through their care journey using HIPAA-compliant SMS, email, and voice messages. With the new MedChat capabilities, patients now have the ability to perform complex tasks by linking directly with live agents using MedChat’s advanced chatbot services. Medchat’s natural language processing (NLP) reads and understands patients’ messages, while its machine learning algorithms adapt over time to provide the most relevant information. It’s symptom checker and triage bot – now embedded within Patient Navigation Manager’s core communications technologies – evaluates 125,000 evidence-based references to diagnose patients and recommend the appropriate care setting.

Since its introduction a year ago, Philips Patient Navigation Manager has experienced widespread adoption among health systems in the USA, generating early success for customers including an 86% reduction in same-day cancellations [1], a 45% reduction in no-shows [2], and a 30% increase in referral conversion efficiency [3]. Philips Patient Navigation Manager easily scales across the enterprise, and is conveniently accessible through a mobile device or computer without the need for patients to download an app.

“Philips continues to demonstrate our ongoing commitment and leadership in patient management and engagement with fully integrated solutions into our suite of smart connected imaging systems,” said Brent Berthy, General Manager of Precision Diagnosis Solutions at Philips. “By combining MedChat’s technology with Philips Patient Navigation Manager, we can help healthcare enterprises deliver streamlined diagnostic workflows that meet the quadruple aim of better patient outcomes, enhanced patient and staff experiences, and lower operational costs due to the elimination of burdensome manual outreach task.”

“Philips Patient Navigation Manager does a great job helping providers communicate with patients while improving outcomes, while MedChat helps make that HIPAA-compliant conversation two-way, real-time, and an enhanced experience,” said Matt Yagey, Founder and CEO at MedChat. “We are excited to bring our integrated solution to Philips customers and also see an enormous need for Patient Navigation Manager among our hundreds of customers.”

The Philips-Medchat collaboration follows a similar enhancement to digitally connect patients to practitioners outside the hospital or clinic. Earlier this year, Philips teamed with openDoctor to integrate real-time patient self-scheduling capabilities into Philips Patient Navigation Manager. The customizable, single-vendor solution for radiology patient management aims to reduce lost slots, improve speed of scheduling, optimize appointment preparation, and improve patient and staff satisfaction.

Philips Patient Navigation Manager, a Software-as-a-Service (SaaS) offering, will be highlighted at this year’s Radiological Society of North America (RSNA) Annual Meeting (November 28 – December 2, 2021, Chicago, U.S.A.). Join Philips at RSNA 2021 where the company will spotlight its latest portfolio of radiology workflow solutions and smart connected imaging systems to increase efficiency and diagnostic confidence in precision care and treatment, and follow @PhilipsLiveFrom for updates throughout RSNA.

[1] Balakrishnan AS, Nguyen HG, Shinohara K, Au Yeung R, Carroll PR, Odisho AY. A Mobile Health Intervention for Prostate Biopsy Patients Reduces Appointment Cancellations: Cohort Study. Journal of medical Internet research. 2019;21(6):e14094.12
[2] Solonowicz O, Stier MW, Kim K, Kupfer SS, Sengupta N. 860 Digital Navigation Improves No Show Rates and Bowel Preparation Quality for Patients Undergoing Colonoscopy – A Randomized Controlled Study. Gastroenterology. 2020;158(6):S-176.13
[3] Feng A, Elias J, Hart K, Roberts P, Laskowski K. Automated Patient Navigation Platform Increases Referral Conversion for Surgical Consultations. Paper presented at: Connected Health Conference 2018; Boston, MA.

For further information, please contact:

Kathy O’Reilly
Philips Global Press Office
Tel.: +1 978-221-8919

Silvie Casanova
Philips North America
Tel: +1 781-879-0692

Matthew Hanis
Tel.: +1 636-537-5454

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 17.3 billion and employs approximately 78,000 employees with sales and services in more than 100 countries. News about Philips can be found at

About MedChat

MedChat, LLC (Charlotte, NC) Hundreds of payers, providers and other healthcare organizations  use MedChat’s communication and automation platform to improve engagement, quality & safety, productivity, and revenue growth.  News about MedChat can be found at


Sannam S4 reveals globally certified International Education Adviser Programme in aim to provide best in class in-country support

NEW DELHI, India, Nov. 22, 2021 (GLOBE NEWSWIRE) — Sannam S4 has achieved full accreditation under the CPD Certification Service for their International Education Adviser Programme, in the top five markets across the globe; US, UK, Canada, New Zealand, and Australia. The Adviser programme is featured within the Sannam S4’s Centre of Excellence, an internal Learning and Development Academy. This prestigious accomplishment reflects the extensive work and effort put into creating a cohesive, practical, and development-focused virtual portal, allowing Sannam S4 employees to further their skills and careers at no cost.

With more than 25 years of industry experience, CPD Certification Services is the gold standard for accreditation of training programmes across a range of industries. A thorough process to determine whether a business meets its high standards is required to achieve accreditation, which Sannam S4 passed with flying colours.

Over a 14-day review and assessment process, CPD Certification Services examined every aspect of the complete Centre of Excellent Learning and Development Academy, which is filled with a range of e-learning materials from videos to reading materials to quizzes and assessments. Once all training content has been reviewed, Sannam S4 received confirmation of their accreditation.

Nikhil Shanker, Executive Director of Human Capital and Talent Acquisition, has this to say about the formal accreditation of the Centre of Excellence Learning and Development Academy:

“We are thrilled to be able to offer our employees an accredited and thoroughly tested online portal for learning and development. Our goal at Sannam S4 is to provide the best possible opportunities for growth and development, both through our academy and our other programmes. Accreditation under the CPD proves the high standard of care we offer to employees and the effort we put into providing them with new areas for growth and learning.”

This accreditation reflects Sannam S4’s continued efforts and commitment to providing its employees with the excellent resources and services needed for career development and on-the-job learning. With the Centre of Excellence updated with the latest materials to ensure continued growth, Sannam S4 strives to provide every member of its team with the tools needed for long-term success.

Sannam S4 is the preferred global partner for strategic and sustainable expansion in international higher education, corporate, nonprofit, and government services. By providing local expertise, a global perspective and data analysis, we help partners confidently explore, enter and expand into dynamic, high-growth markets. Our international footprint encompasses India, China, Malaysia, Singapore, Vietnam, the UK and the USA.

Established in 2008, Sannam S4 has supported a wide variety of organisations to enter new countries and achieve their expansion goals. In the process, we have developed robust partnerships with stakeholders across the globe, including the US International Trade Administration, the US Department of Commerce, the UK Department of International Trade, as well as government agencies in Australia, Canada, India, Ireland and New Zealand.

We offer value to our partners by delivering market-leading, value-added services that drive positive, ROI-focused outcomes in higher education with student recruitment, partnership development and enrollment growth. For commercial and nonprofit organisations, we are focussed on optimising complex international finance, HR and compliance related operations to accelerate global expansion in Asia. Our products are designed to address the needs of our partners and maximize current opportunities while remaining agile in times of market volatility.


Stacey Lane- Head of Communications

Apollo Funds to Acquire 50% Stake in Broad Reach Power from EnCap

  • Apollo Funds and existing EnCap-led shareholder group also commit to invest up to $400 million of new equity to accelerate Broad Reach Power’s growth and expansion plans
  • Transaction marks first sale for EnCap Energy Transition Fund I
  • Extends Apollo’s energy transition activity with premier, vertically integrated platform

NEW YORK and HOUSTON, Nov. 22, 2021 (GLOBE NEWSWIRE) — Apollo (NYSE: APO) and EnCap Energy Transition Fund I (“EETFI”) today announced that funds managed by Apollo affiliates (the “Apollo Funds”) have agreed to acquire a 50% stake in Broad Reach Power LLC (“Broad Reach”), a leading utility-scale energy storage and renewable energy platform in the US. The Apollo Funds will acquire the stake from existing investor EnCap Investments L.P. (“EnCap”) and its co-investment partners Yorktown Partners and Mercuria Energy. EnCap and its co-investment partners will retain the other 50% stake and, together with the Apollo Funds, commit to invest up to $400 million of additional equity to fund Broad Reach’s continued expansion and growth pipeline.

Broad Reach is a leading energy storage platform in the US, applying advanced energy storage technology and power market analytics to improve the performance of renewable and power generation facilities. The company has more than 1.4 gigawatt hours of storage assets in operation or under construction and controls a 21-gigawatt (GW) portfolio of utility-scale wind, solar and energy storage power projects across the country.

“At Apollo we have been highly active in the energy transition, and we are thrilled to join EnCap in this investment in Broad Reach, which in our view is the premier energy storage leader in the US,” said Geoff Strong, Senior Partner and Co-Head of Infrastructure and Natural Resources at Apollo. “Broad Reach has a scaled, high-performing platform that is well positioned for strong continued growth, particularly as the shift to more intermittent clean energy increases volatility and drives demand for energy storage.”

Broad Reach CEO Steve Vavrik said, “Apollo is a world-leading investor with the expertise, capital and motivation to invest in a wide range of energy transition companies, and we are excited to welcome them to Broad Reach alongside EnCap, Yorktown Partners and Mercuria Energy. We view this as a significant vote of confidence in Broad Reach and our exciting growth prospects, as we continue to execute on our long-term goal to supply the nation with clean, reliable and affordable power.”

Corinne Still, Principal at Apollo, commented “This transaction unites Apollo with a terrific shareholder group that has demonstrated significant conviction, commitment, and success in building a large and nimble clean energy platform. We look forward to collectively supporting Steve and his team in their future growth.”

“Broad Reach has emerged as a disruptor in the dramatic transformation of the US electricity sector. We believe this transaction both validates the value created by EnCap’s sponsorship of Broad Reach and allows us to continue to participate in its dominant position in the market,” said EnCap Energy Transition Managing Partner Shawn Cumberland, also chairman of the Broad Reach board of directors. “Apollo is a sophisticated and experienced energy transition and power industry investor and will be an extremely valuable member in the expanded partnership to accelerate Broad Reach’s growth.”

EnCap has been one of the most aggressive pioneer investors in the fast-growing US battery storage business. EnCap’s energy transition platform established Broad Reach in 2019 by bringing together professionals with extensive experience in battery storage systems and proven developers with long track records in renewables. The acquisition by the Apollo Funds will also represent the first sale by EnCap’s $1.2 billion Energy Transition Fund I. In addition to Broad Reach, EETFI controls a robust portfolio that includes Catalyze Energy (distributed commercial and industrial solar plus batteries), Solar Proponent (large scale solar), Triple Oak Power (wind power) and Arbor Renewable Gas (clean fuels), among others.

For the Apollo Funds, this extends a long track record of investing in or lending to companies supporting the clean energy transition. Most recently this includes committing more than $820 million of funding to NextEra Energy Partners’ for its stake in a renewable energy generation portfolio; forming a new venture with Johnson Controls to provide sustainability and energy efficiency services; investing in US Wind, an offshore wind developer; forming a joint venture to accelerate the growth of renewable energy royalties company Great Bay Renewables; investing in Stagecoach Royalty, a renewable energy land royalties platform; acquiring a majority stake in Arlington Valley, a utility scale solar asset; acquiring Tullahennel, a wind power asset in Ireland; and investing in sustainable bioenergy producer AS Graanul Invest.

The transaction is subject to customary closing conditions and expected to be completed by year-end 2021. White & Case LLP served as the legal advisor and Citi served as the sole financial advisor to EnCap and Broad Reach. Kirkland & Ellis LLP served as legal counsel to the Apollo Funds.

About Broad Reach
Broad Reach Power is a leading utility-scale storage platform in the United States. Based in Houston, the company owns a 21 GW portfolio of utility-scale solar and energy storage power projects in Montana, California, Wyoming, and Texas which give utilities, generators and customers access to technological insight and tools for managing merchant power risk so they can better match supply and demand. For more information about the company, visit

About Apollo
Apollo is a high-growth, global alternative asset manager. We seek to provide our clients excess return at every point along the risk-reward spectrum from investment grade to private equity with a focus on three business strategies: yield, hybrid and equity. Through our investment activity across our fully integrated platform, we serve the retirement income and financial return needs of our clients, and we offer innovative capital solutions to businesses. Our patient, creative, knowledgeable approach to investing aligns our clients, businesses we invest in, our employees and the communities we impact, to expand opportunity and achieve positive outcomes. As of September 30, 2021, Apollo had approximately $481 billion of assets under management. To learn more, please visit

About EnCap Investments L.P.
Since 1988, EnCap Investments has been the leading provider of venture capital to the independent sector of the US energy industry. The firm has raised 22 institutional investment funds totaling approximately $38 billion and currently manages capital on behalf of more than 350 US and international investors. EnCap Energy Transition platform is led by four Managing Partners, each with 25-30 years of experience in renewables and power. For more information, please visit

For Apollo:
Noah Gunn
Global Head of Investor Relations
(212) 822-0540

Joanna Rose
Global Head of Corporate Communications
(212) 822-0491

For EnCap:
Charles Bauer
Partner and Head of Investor Relations
(713) 659-6100

North America
Ten10 Group
Casey Nikoloric
303.433.4397, x101 o
303.507.0510 m

EMEA & Asia
Prosek Partners
Philip Walters
+44 (0) 7773331589

Sword GRC Wins Rising Star Award From Chartis Research

Global ERM software market-leader Sword GRC secures RiskTech100® 2022 ‘Rising Star’ accolade.

Chartis Risk Tech 100 2022 Rising Star Award

Chartis Risk Tech 100 2022 Rising Star Award

MAIDENHEAD, England, Nov. 22, 2021 (GLOBE NEWSWIRE) — Sword GRC, a provider of specialist risk, compliance and governance software and services is proud to announce that it has been recognized by Chartis Research as a ‘Rising Star’ in its 2022 RiskTech100® Awards, a unique benchmark ranking the top 100 players in the global risk technology space.

The ‘Rising Star’ award highlights up-and-coming risk management software vendors that are, in the opinion of Chartis Research analysts, the companies to watch. Sword GRC’s best-in-class ERM solutions put risk, governance and compliance management at the heart of strategic and operational decision-making, enabling its customers within core global markets of infrastructure, energy, aerospace and defense, construction and government to achieve both project and longer-term strategic business objectives.

“We’re exceptionally pleased to feature in the RiskTech100® by Chartis Research, a leading provider of independent research and analysis on the global market for risk technology,” said Keith Ricketts, VP of Marketing at Sword GRC. “With a multi-million-dollar investment in leveraging digital technologies that enable world-class organizations to make better, risk-based decisions that optimize business performance, provide greater resilience and agility, Sword GRC is very much on the ascendant, meeting the diverse needs and challenges of our customers and keeping them ahead of the GRC curve within their respective industries.”

Commenting on the award win, Sid Dash, Research Director at Chartis Research, said: “Sword GRC’s RiskTech100® award reflects its innovation and customer focus, and the contribution that its risk management solutions make in driving and supporting enterprises’ performance and best practices.”

– Ends –

Press Enquiries:

Keith Ricketts, VP of Marketing


M: 07894 608435

About Sword GRC

Sword GRC provides an award-winning platform for Governance, Risk and Compliance, made up of best-of-breed solutions that address the requirements of all enterprise market sectors. With a long and distinguished heritage, Sword GRC brings together a suite of complementary products in the GRC space available either as a cloud solution or standalone on-premises installations.

With a strong focus on driving fast time to value, and harnessing the latest technologies, Sword GRC delivers a versatile range of solutions that support better business decisions through a single view of risk to support enterprise-wide risk-based compliance. The Sword GRC product set covers Risk, Audit, Compliance, Policy Management and Incident Management

About Chartis Research

Chartis Research is the leading provider of research and analysis on the global market for risk technology. It is part of Infopro Digital, which owns market-leading brands such as Risk and WatersTechnology. Chartis’ goal is to support enterprises as they drive business performance through improved risk management, corporate governance and compliance, and to help clients make informed technology and business decisions by providing in-depth analysis and actionable advice on virtually all aspects of risk technology.

For more information, please visit: Chartis Research

Related Files

Chartis_RiskTech100 2022_Rising Star logo.png

Related Images

Image 1: Chartis Risk Tech 100 2022 Rising Star Award

Chartis Risk Tech 100 2022 Rising Star Risk Management Software Award

This content was issued through the press release distribution service at


Philips again a leading company in the Dow Jones Sustainability Indices

November 22, 2021

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it has once again been recognized as one of the leading companies for sustainability performance in the global 2021 Dow Jones Sustainability Indices (DJSI) list. Scoring 81 out of 100 points in the DJSI Health Care Equipment & Supplies industry group, Philips again achieved a #2 ranking in the leading sustainability benchmark.

Evaluated across the Environmental, Social and Governance & Economic dimensions of DJSI’s sustainability review, Philips received the maximum scores (100/100) in the Environmental reporting, Health outcome contribution and Social reporting categories. In addition, Philips leads the industry in among others the Supply Chain Management, Tax Strategy, Innovation Management, Operational Eco-Efficiency, Climate Strategy and Human Rights categories.

“I am very pleased that our actions to do business responsibly and sustainably continue to be recognized by the Down Jones Sustainable Index,” said Frans van Houten, CEO of Royal Philips. “As part of our ongoing commitment to making the world healthier and more sustainable through innovation, we will continue to raise the bar for ourselves and our partners, as evidenced for example by our recent climate action to drive significant reduction of greenhouse gas emissions in our supply chain.”

Comprehensive ESG framework
Philips employs a comprehensive set of commitments across all the Environmental, Social and Governance (ESG) dimensions to guide the execution of company strategy and support its contribution to the UN Sustainable Development Goals. Philips is already carbon neutral in its operations and is set to further reduce its CO2 emissions in line with 1.5°C global warming. The company also set ambitious circular economy objectives, such as generating 25% of its revenue from circular products, services and solutions. As part of the company’s 2025 target to improve the lives of 2 billion people a year, Philips is committed to improving access to care for 300 million people in underserved communities.

Philips was the first health technology company to have its carbon emission targets for the 2020 – 2040 period assessed and approved by the Science-Based Targets initiative (STBi). Philips received further recognition for its ESG performance, achieving top positions in Sustainalytics rankings and eight consecutive years on the CDP Climate Change A-list. In March 2021, the company was awarded a top ESG score of 90 out of 100 by S&P Global Ratings. Philips also achieved second place in 2020 on Wall Street Journal’s 100 Most Sustainably Managed Companies in the World.

For further information, please contact:

Ben Zwirs
Philips Global Press Office
Tel.: +31 6 15213446

Derya Guzel
Philips Investor Relations
Tel.: +31 20 59 77055

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 17.3 billion and employs approximately 78,000 employees with sales and services in more than 100 countries. News about Philips can be found at


Degreed is named a Leader in Learning Management Systems and Experience Platforms

PLEASANTON, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) — Degreed was among the select companies that Forrester invited to participate in The Forrester Wave™: Learning Management Systems and Experience Platforms, Q4 2021. In this evaluation, Degreed was cited as a Leader and its top scores were in the talent ecosystem integration, product vision, execution roadmap, and commercial model criteria.

Forrester employs a rigorous process to create a Forrester Wave. Highlights include generating a detailed taxonomy of product attributes, gathering and validating data, and creating the Forrester Wave graphic.

Per the report, “Degreed is investing in adding select learning management system (LMS) functionality while doubling down on its commitment to bring opportunities to ‘learn by doing’ and ‘signals’ about learning from all parts of the work ecosystem to craft the learner experience and provide robust workforce data to the employer…Degreed’s user interface is a strength, as is its ability to bring together data and analytics from many sources.”

Todd Tauber, SVP Strategy at Degreed said, “Degreed was the first to define the LXP and the team continues to build on this innovation with additional functionality in experiential learning and internal mobility, and skill analytics with the launch of Degreed Intelligence. The team is grateful that Forrester’s rigorous research has, in our opinion, validated the leadership and differentiation actions Degreed has taken this year.”

According to Forrester, “Companies that invest in a variety of skills development platforms and place a strong focus on skills and career development will find Degreed a robust solution that is not limited by prioritizing any one vendor.”

Editor’s notes

About Degreed

Degreed is the workforce upskilling platform chosen by one in three Fortune 50 companies. We connect all your learning and internal mobility opportunities to intelligence on the skills your business needs next. And we do it all in one simple, fluid, skill-building experience that’s powered by your people’s expertise and interests. So you can transform your workforce from within. Founded in 2012, Degreed is headquartered in Pleasanton, California, with additional offices in Salt Lake City, New York, London, Amsterdam, and Brisbane.

Learn more about Degreed: Website | YouTube | LinkedIn | Twitter

Sarah Danzl
Head of Global Communications, Degreed

Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor

Xencor receives rights to additional equity in Zenas as upfront payment and is eligible for up to $480 million in potential milestone payments and royalties on net sales of commercialized products

Obexelimab is a novel bifunctional antibody with first-in-class potential to treat autoimmune diseases

MONROVIA, Calif., HONG KONG and BOSTON, Nov. 21, 2021 (GLOBE NEWSWIRE) — Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, and Zenas BioPharma (“Zenas”), a global biopharmaceutical company based in the USA and China committed to the development and delivery of immune-based therapies, today announced that Zenas has acquired from Xencor exclusive worldwide rights to develop, manufacture and commercialize the investigational antibody obexelimab.

Obexelimab is a potential first-in-class bifunctional antibody that targets CD19 with its variable domain and uses Xencor’s XmAb® Immune Inhibitor Fc Domain to target FcγRIIb, a receptor that inhibits the function of B-cells, which are important components in the immune system. Xencor demonstrated through early-stage clinical studies that obexelimab effectively inhibits B-cell function without depleting the cells and generates an encouraging treatment effect in patients with multiple autoimmune diseases.

“Zenas is advancing a broad pipeline of differentiated drug candidates that are intended to bring best-in-class innovation to patients with underserved medical needs,” said Hua Mu, Ph.D., MD, president and chief executive officer at Zenas. “Today, we are pleased to add obexelimab to our portfolio, and based on its clinical profile, we believe it is positioned as a first-in-class candidate with the potential to treat numerous autoimmune diseases.”

“Obexelimab’s highly potent and broad blockade of B-cell activation—without depleting B cells—differentiates it from other B-cell targeting therapies, and it has demonstrated disease-modifying activity in settings where B-cell inhibition is a proven strategy,” said Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor. “In Zenas BioPharma, we have found a partner committed to broadly and aggressively developing therapeutics like obexelimab for patients with autoimmune diseases, enabling Xencor’s continued focus on the growing opportunities provided by our XmAb bispecific antibody and cytokine pipeline.”

Under the terms of the new agreement, Zenas will issue to Xencor a warrant giving Xencor the right to acquire additional Zenas equity, such that Xencor’s total equity in Zenas would be 15% of its fully diluted capitalization following the closing of Zenas’ next round of equity financing, subject to certain requirements. Xencor previously received equity in Zenas under a separate license agreement. Xencor is also eligible to receive up to $480 million based on the achievement of certain clinical development, regulatory and commercialization milestones and is eligible to receive tiered, mid-single digit to mid-teen percent royalties upon commercialization of obexelimab, dependent on geography. Zenas will have sole responsibility for advancing the research, development, regulatory and commercial activities of obexelimab worldwide.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 22 candidates engineered with Xencor’s XmAb® technology are in clinical development internally and with partners. Xencor’s XmAb antibody engineering technology enables small changes to the structure of proteins resulting in new mechanisms of therapeutic action. For more information, please visit

About Zenas BioPharma

Zenas BioPharma is a global biopharmaceutical company based in the USA and China committed to becoming a leader in the development and delivery of immune-based therapies for patients in the US, China and around the world. Zenas is rapidly advancing a deep pipeline of innovative therapeutics that continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit and follow us on Twitter at @ZenasBioPharma and LinkedIn.

Xencor Forward-Looking Statements

Certain statements contained in this press release may constitute forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include statements that are not purely statements of historical fact, and can generally be identified by our use of words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “seek,” “look forward,” “believe,” “committed,” “investigational,” and similar terms, or by express or implied discussions relating to the development of obexelimab as a potential treatment for patients with autoimmune diseases; the commercial potential of obexelimab; the safety, tolerability, efficacy and pharmacokinetics of obexelimab; the quotations from Xencor’s president and chief executive officer; and other statements that are not purely statements of historical fact. Such statements are made on the basis of the current beliefs, expectations, and assumptions of the management of Xencor and are subject to significant known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements and the timing of events to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. Such risks include, without limitation, the risks associated with the process of discovering, developing, manufacturing and commercializing drugs that are safe and effective for use as human therapeutics and other risks described in Xencor’s public securities filings. For a discussion of these and other factors, please refer to Xencor’s annual report on Form 10-K for the year ended December 31, 2020 as well as Xencor’s subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended to date. All forward-looking statements are qualified in their entirety by this cautionary statement and Xencor undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.


Xencor Investor Contact:
Charles Liles

Xencor Media Contact:
Jason I. Spark
Canale Communications

Zenas Investor Contact:

Zenas Media Contact:
Lauren Bartlett

Zenas BioPharma เข้าซื้อสิทธิ์แต่เพียงผู้เดียวทั่วโลกสำหรับ Obexelimab จาก Xencor

Xencor ได้รับกรรมสิทธิหุ้นส่วนเพิ่มเติมใน Zenas ในส่วนของการชำระเงินล่วงหน้า และมีสิทธิ์ในการชำระเงินตามเป้าหมายและค่าลิขสิทธิ์จากยอดขายสุทธิของผลิตภัณฑ์เชิงพาณิชย์ถึง 480 ล้านดอลลาร์สหรัฐ

Obexelimab คือแอนติบอดี Bispecific ใหม่ ซึ่งมีศักยภาพในการรักษาโรคภูมิต้านทานเนื้อเยื่อตัวเองเหนือกว่าชนิดอื่น

มอนโรเวีย, แคลิฟอร์เนีย, ฮ่องกง และบอสตัน, Nov. 22, 2021 (GLOBE NEWSWIRE) — Xencor, Inc. (NASDAQ: XNCR) ซึ่งเป็นบริษัทชีวเภสัชภัณฑ์ในระยะที่มีอาการของโรคที่พัฒนาโมโนโคลนอลแอนติบอดีที่ผ่านการวิศวกรรมและไซโตไคน์สำหรับการรักษาโรคมะเร็งและโรคภูมิต้านทานเนื้อเยื่อตัวเอง และ Zenas BioPharma (ต่อไปนี้จะเรียกว่า “Zenas”) ซึ่งเป็นบริษัทชีวเภสัชภัณฑ์ระดับโลกที่มีฐานการผลิตอยู่ในสหรัฐอเมริกาและจีน มุ่งมั่นที่จะพัฒนาและส่งมอบการรักษาด้วยภูมิคุ้มกันบำบัด วันนี้ ได้ประกาศว่า Zenas ได้เข้าซื้อสิทธิ์แต่เพียงผู้เดียวทั่วโลกจาก Xencor ในการพัฒนา ผลิต และทำการค้า Obexelimab ซึ่งเป็นแอนติบอดีที่อยู่ภายใต้การวิจัย

Obexelimab คือแอนติบอดี Bifunction ที่มีศักยภาพเหนือกว่าชนิดอื่นที่จะจับ CD19 โดยมีโดเมนที่แปรผันได้ และใช้ XmAb® Immune Inhibitor Fc Domain ของ Xencor เพื่อจับ FcγRIIb ซึ่งเป็นตัวรับที่ยับยั้งการทำงานของเซลล์บี ซึ่งเป็นส่วนประกอบที่สำคัญในระบบภูมิคุ้มกัน Xencor ได้แสดงให้เห็นผ่านการศึกษาวิจัยทางคลินิกในระยะแรกโดยพบว่า Obexelimab สามารถยับยั้งการทำงานของเซลล์บีได้อย่างมีประสิทธิภาพ โดยไม่ต้องลดจำนวนเซลล์ และส่งเสริมการรักษาผู้ป่วยที่มีโรคภูมิต้านทานเนื้อเยื่อตัวเองหลายชนิด

“Zenas ได้สร้างความก้าวหน้าให้กับการทดสอบทางยาชนิดต่างๆ ซึ่งมีวัตถุประสงค์เพื่อนำเสนอนวัตกรรมที่ดีที่สุดให้กับผู้ป่วยที่ไม่ได้รับการดูแลทางการแพทย์อย่างเพียงพอ” Hua Mu, Ph.D., MD, ประธานและประธานเจ้าหน้าที่บริหารของ Zenas กล่าว “วันนี้ เรายินดีที่จะเพิ่ม Obexelimab ลงในกลุ่มผลิตภัณฑ์ของเรา และจากประวัติทางการวิจัยของยานี้ เราเชื่อว่ามีความเหมาะสมที่จะเป็นยาวิจัยที่ดีที่สุด ซึ่งมีศักยภาพในการรักษาโรคภูมิต้านทานเนื้อเยื่อตัวเองหลากหลายชนิด”

“ศักยภาพที่สูงและการปิดกั้นการกระตุ้นเซลล์บีชนิดต่างๆ ของ Obexelimab โดยไม่ทำให้เซลล์บีลดจำนวนลง สร้างความแตกต่างจากการรักษาที่เจาะจงเซลล์บีอื่นๆ และได้แสดงให้เห็นถึงการปรับเปลี่ยนการดําเนินโรคในสภาพแวดล้อมที่การยับยั้งเซลล์บีเป็นกลยุทธ์ที่ได้รับการพิสูจน์แล้ว” Bassil Dahiyat, Ph.D., ประธานและประธานเจ้าหน้าที่บริหารของ Xencor “ที่ Zenas BioPharma เราได้พบกับพันธมิตรที่มุ่งมั่นในการพัฒนาทางการรักษาอย่างกว้างขวางและเชิงรุก เช่น Obexelimab สำหรับผู้ป่วยที่มีโรคภูมิต้านทานเนื้อเยื่อตัวเอง ช่วยให้ Xencor สามารถมุ่งมั่นอย่างต่อเนื่องในโอกาสของการเติบโตจากกลุ่มผลิตภัณฑ์แอนติบอดี Bispecific XmAb และไซโตไคน์ของเรา” ตามข้อกำหนดในข้อตกลงใหม่ Zenas จะออกการรับประกันให้กับ Xencor โดยให้สิทธิ์ Xencor ในการเข้าซื้อกรรมสิทธิหุ้นส่วนของ Zenas เพิ่มเติม จนกว่าจะมีกรรมสิทธิหุ้นส่วนทั้งหมดของ Xencor ใน Zenas ถึง 15% ของมูลค่าหลักทรัพย์หลังการเสนอขายหุ้น (Fully diluted) หลังจากการปิดการจัดหาเงินทุนโดยออกหุ้นเพิ่มของ Zenas ภายใต้ข้อกำหนดบางประการ ก่อนหน้านี้ Xencor ได้รับกรรมสิทธิหุ้นส่วนใน Zenas ภายใต้ข้อตกลงใบอนุญาตแยกกัน Xencor ยังมีสิทธิ์ได้รับสูงสุด 480 ล้านดอลลาร์สหรัฐเมื่อบรรลุเป้าหมายการพัฒนาทางคลินิก การกำกับดูแล และการทำการค้าบางอย่าง และมีสิทธิ์ได้รับค่าลิขสิทธิ์แบบเป็นชั้น เป็นเปอร์เซ็นต์ระหว่างตัวเลขหลักเดียวในระดับกลาง ถึงตัวเลขสองหลักในระดับกลาง ตามการค้าของ Obexelimab ขึ้นอยู่กับภูมิศาสตร์ Zenas จะต้องรับผิดชอบแต่เพียงผู้เดียวในสร้างความก้าวหน้าให้กับการวิจัย การพัฒนา กฎระเบียบ และกิจกรรมทางการค้า Obexelimab ทั่วโลก

เกี่ยวกับ Xencor, Inc

Xencor คือบริษัทชีวเภสัชภัณฑ์ในระยะที่มีอาการของโรคที่พัฒนาโมโนโคลนอลแอนติบอดีที่ผ่านการวิศวกรรมและไซโตไคน์สำหรับการรักษาโรคมะเร็งและโรคภูมิต้านทานเนื้อเยื่อตัวเอง ในปัจจุบัน ตัวยา 22 ตัวที่ที่ผ่านการออกแบบด้วยเทคโนโลยี XmAb® ของ Xencor อยู่ในการพัฒนาทางคลินิกทั้งภายในและกับคู่ค้า เทคโนโลยีการออกแบบแอนติบอดี XmAb ของ Xencor ช่วยให้สามารถเปลี่ยนแปลงโครงสร้างของโปรตีนขนาดเล็ก ซึ่งเป็นผลให้เกิดกลไกการรักษารูปแบบใหม่ สำหรับข้อมูลเพิ่มเติม โปรดไปที่

เกี่ยวกับ Zenas BioPharma

Zenas BioPharma เป็นบริษัทชีวเภสัชภัณฑ์ระดับโลกที่มีฐานการผลิตอยู่ในสหรัฐอเมริกาและจีนมุ่งมั่นที่จะเป็นผู้นำระดับโลกด้านการพัฒนาและการส่งมอบการรักษาด้วยภูมิคุ้มกันบำบัดสำหรับผู้ป่วยในสหรัฐอเมริกา จีน และทั่วโลก Zenas กำลังพัฒนากลุ่มผลิตภัณฑ์เชิงลึกด้านการบำบัดอันล้ำสมัยอย่างรวดเร็วซึ่งเติบโตอย่างต่อเนื่องผ่านกลยุทธ์การพัฒนาธุรกิจที่ประสบความสำเร็จของเรา “ทีมผู้นำที่มีประสบการณ์และเครือข่ายพันธมิตรทางธุรกิจของเราจะผลักดันความเป็นเลิศในการดำเนินงานเพื่อนำเสนอวิธีการรักษาที่เปลี่ยนแปลงได้เพื่อปรับปรุงชีวิตของผู้ที่ประสบโรคภูมิต้านทานเนื้อเยื่อตัวเองและโรคหายาก” สำหรับข้อมูลเพิ่มเติมเกี่ยวกับ Zenas BioPharma โปรดไปที่ และติดตามพวกเราบน Twitter ได้ที่ @ZenasBioPharma และ LinkedIn

ข้อความเชิงคาดการณ์เหตุการณ์ในอนาคตของ Xencor

บางข้อความในข่าวประชาสัมพันธ์ฉบับนี้อาจเป็นข้อความเชิงคาดการณ์เหตุการณ์ในอนาคตภายใต้ความหมายของกฎหมายหลักทรัพย์ที่มีผลบังคับใช้ ข้อความเชิงคาดการณ์เหตุการณ์ในอนาคตประกอบด้วยข้อความที่ไม่ได้เป็นข้อความด้านข้อเท็จจริงทางประวัติศาสตร์เท่านั้น และโดยทั่วไปแล้ว สามารถระบุได้จากการใช้คำของเรา เช่น “มีศักยภาพ” “สามารถ” “จะ” “วางแผน” “อาจจะ” “อาจ” “สามารถ” “คาดว่า” “คาดการณ์ว่า” “หวังว่า” “เชื่อว่า” “มุ่งมั่น” “วิจัย” หรือคำที่คล้ายกัน หรือโดยการหารือโดยชัดแจ้งหรือโดยนัยเกี่ยวกับการพัฒนา Obexelimab เป็นการรักษาที่มีศักยภาพสำหรับผู้ป่วยที่เป็นโรคภูมิต้านทานเนื้อเยื่อตัวเอง ;ศักยภาพทางการค้าของ Obexelimab; ความปลอดภัย ความอดทนรับยาได้ ประสิทธิภาพ และเภสัชจลนศาสตร์ของ Obexelimab; คำอ้างอิงจากประธานและประธานเจ้าหน้าที่บริหารของ Xencor; และข้อความอื่นๆ ที่ไม่ได้เป็นเพียงข้อความด้านข้อเท็จจริงทางประวัติศาสตร์เท่านั้น ข้อความดังกล่าวนั้นเขียนขึ้นบนพื้นฐานของความเชื่อ ความคาดหวัง และสมมติฐานในปัจจุบันของฝ่ายบริหารจัดการของ Xencor และอยู่ภายใต้ความเสี่ยงที่ทราบชัดแจ้งแล้วและยังไม่ทราบ ความไม่แน่นอน และปัจจัยอื่นๆ ซึ่งอาจส่งผลให้เกิดผลลัพธ์ที่แท้จริง ประสิทธิภาพ หรือความสำเร็จ และเวลาของเหตุการณ์ที่จะแตกต่างไปจากที่ได้ระบุเอาไว้ในข้อความดังกล่าวอย่างมาก ดังนั้น จึงไม่ควรอ่านข้อความเหล่านี้เพื่อเป็นการรับประกันผลการปฏิบัติงานหรือผลลัพธ์ในอนาคต ความเสี่ยงดังกล่าวรวมถึงแต่ไม่จำกัดเฉพาะความเสี่ยงที่เกี่ยวข้องกับกระบวนการค้นพบ พัฒนา ผลิต และทำการค้ายาที่ปลอดภัยและมีประสิทธิภาพในการรักษาโรคของมนุษย์และความเสี่ยงอื่นๆ ตามที่อธิบายไว้ในเอกสารด้านการรักษาความปลอดภัยที่ยื่นต่อสาธารณะของ Xencor สำหรับการอภิปรายเกี่ยวกับปัจจัยเหล่านี้และปัจจัยอื่นๆ โปรดดูที่รายงานประจำปีของ Xencor ในแบบฟอร์ม 10-K สำหรับปีที่สิ้นสุดวันที่ 31 ธันวาคม 2020 รวมถึงเอกสารเพิ่มเติมที่ Xencor ยื่นต่อสำนักงานคณะกรรมการกำกับหลักทรัพย์และตลาดหลักทรัพย์ คุณไม่ควรให้ความเชื่อถือข้อความเชิงคาดการณ์เหตุการณ์ในอนาคตนี้มากเกินไป ซึ่งเป็นจริงเฉพาะวันที่ที่ระบุไว้เท่านั้น ข้อควรระวังนี้จัดทำขึ้นภายใต้บทบัญญัติการจำกัดความรับผิดชอบของกฎหมายปฏิรูปการฟ้องร้องคดีหลักทรัพย์ส่วนบุคคลปี 1995 ตามที่ได้รับการแก้ไขปรับปรุงจนถึงปัจจุบัน ข้อความเชิงคาดการณ์เหตุการณ์ในอนาคตทั้งหมดมีคุณสมบัติครบถ้วนสมบูรณ์ตามประกาศข้อควรระวังนี้และ Xencor ไม่มีภาระผูกพันที่จะแก้ไขหรือปรับปรุงข่าวประชาสัมพันธ์ฉบับนี้เพื่อให้สะท้อนถึงเหตุการณ์หรือสถานการณ์หลังจากวันที่ดังกล่าว เว้นแต่กฎหมายกำหนดไว้


ติดต่อนักลงทุนของ Xencor:
Charles Liles

ติดต่อด้านสื่อของ Xencor:
Jason I. Spark
Canale Communications

ติดต่อนักลงทุนของ Zenas:

ติดต่อด้านสื่อของ Zenas:
Lauren Bartlett

Joint venture between telecom giants True, Dtac announced

Thailand’s Charoen Pokphand (CP) Group and Norway’s Telenor Group jointly announced an “equal partnership” for the US$ 200-million joint venture, with a focus on tech start-up investment today (Monday).

The news came after rumours swirling over the past couple weeks about a merger between the two telecom giants True and Dtac or a takeover. On Friday, it was reported that CP and Telenor were discussing a merger, but both companies did not confirm the decision until now.

CP Group CEO and Chairman of the Board of True Corporation Supachai Chearavanont said at a Memorandum of Understanding that the telecom landscape has changed rapidly over the past several years, with new technologies, a broader market for competition and proposals for new forms of digital services from major telecom players.

These factors, he said, are forcing telecom operators to make adjustments quickly.

“Today is a step in that direction. We hope to empower a whole new generation to fulfil their potential to become digital entrepreneurs, leveraging an advanced telecom infrastructure. The emergence in Thailand of IoT (Internet of Things), AI, Cloud and new generations of mobile network technologies will have a huge effect on the way we do everything,” he said.

Supachai said the telecom and technology sectors are key to enabling Thailand to move up the development curve and to create broad-based prosperity.

“As a telecom-tech company, we can help unleash the enormous potential of Thai businesses and digital entrepreneurs, as well as attract more of the best and the brightest from around the world to do business in our country,” he said

President and CEO of Telenor Group Sigve Brekke said that the agreement today will help strengthen Telenor’s business base in Asia and create more value and market development in this region in the long term.

Executive Vice President of Telenor Group and Head of Telenor Asia Jørgen A. Rostrup said this will advance Telenor’s strategy to strengthen their presence in Asia, create value and support long-term market development in the region.

He added that Telenor has a long-standing commitment to both Thailand and the Asian region, and this collaboration will strengthen it further. Access to new technologies and the best human capital will make a vital contribution to the new company.”

Mr. Rostrup disclosed that the new company has the intention to raise venture capital funding of USD 100-200 million, together with partners, to invest in promising digital start-ups, focusing on new products and services for the benefit of all Thai consumers.

Representatives of True and Dtac are due to meet with the Thai National Broadcasting and Telecommunications Commission today and tomorrow to clarify details of the potential merger.

Source: Thai Public Broadcasting Service

21 drown on flooded causeway in Myanmar

21 people have drowned, as thousands of worshippers attempted to cross a flooded causeway in Myanmar, after making merit at a Buddhist pagoda.

The incident occurred as thousands of people were returning from the Kyeik Hne Pagoda, located on rocks roughly two kilometres off the shore, near the town of Thanbyuzayat in southern Mon state, according to a Thai PBS reporter in Mae Sot district of Thailand’s Tak province

Worshippers accessed the pagoda using a tidal causeway. After worship, while they were returning to the shore, the tide rose rapidly, assisted by strong gusts of wind, and many fell from the crowded causeway into the sea.

Rescue workers said the causeway normally opens at 6.30am, but the worshippers had tried to cross earlier, when the tidewas too high to make the journey safely.

A local resident also told reporters that the causeway, which is only 4 metres wide, is not marked clearly enough, making it difficult to navigate.

Source: Thai Public Broadcasting Service